Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flex-Up: Upadacitinib Dose-Flexibility in Atopic Dermatitis
NCT05507580Phase 4Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 4 trial of upadacitinib in atopic dermatitis (AD), sponsored by AbbVie Inc.. Started May 2023; status: completed.
02
Drugs
upadacitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05507580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05507580.